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ABBREVIATIONS 
a — Lp = alpha lipoprotein 
apo— = apolipoprotein 
BCM = body cell mass 
BW = body weight 
EAA = essential amino-acids 
EAAH = essential amino-acids and histidine in proportions according to Rose 
FFA = non-esterified fatty acids 
GFR = glomerular filtration rate 
HDL = high density lipoproteins 
HLP = hyperlipoproteinemia 
HTG = hepatic triglyceride lipase 
I LDL = intermediate low density lipoproteins 
1VFTT = intravenous fat tolerance test 
IVGTT = intravenous glucose tolerance test 
LCAT = lecithin: cholesterol acyl transferase 
LDL = low density lipoproteins 
LPL = lipoprotein lipase 
PHLA = post-heparin lipolytic activity 
SW = standard weight for height 
TBK = total body potassium 
T BW = total body water 
TG = triglycerides 
UC = ultracentrifugation analysis 
VLDL = very low density lipoproteins 
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INTRODUCTION 
The uremic syndrome is the result of derangement of not only excretory but also homeo-
static, endocrine and metabolic functions of the renal tissue. Furth ermore, it is also in­
fluenced by the attempts of the organism to adapt to these abnormalities. 
In renal failure various substances accumulate in body fluids, particularly nitrogen-con­
taining metabolites, among which urea dominates. Patients with advanced uremic symp­
toms often have high serum urea levels and improvement of symptoms during treatment, 
whether dietary t reatment or dialysis is often linked to the reduction of urea levels. How­
ever, several studies have clearly demonstrated that urea is not responsible for uremic 
toxicity in the levels that occurs in renal failure but can serve as a marker for the accumu­
lation of other nitrogenous metabolites, possibly toxic and appearing in much lower con­
centrations18' 20'66'74. 
In renal failure there are disturbances of fluid and electrolyte homeostasis, with loss of 
the ability to adapt to changes in fluid and electrolyte intake or loss. 
The importance of the kidneys as metabolically active organs becomes apparent in renal 
failure61. Impaired erythropoetin production or hydroxylation of 25-hydroxycholecalci-
ferol leads to anemia or development of renal osteodystrophy. Furthermore, the meta­
bolic clearance by the kidney of insulin, glucagon, cyclic AMP and other metabolically 
active substances is greatly reduced and may be important for the uremic toxicity74. 
Changes in the intracellular milieu have been demonstrated in renal failure in man, main­
ly in white blood cells112'127 and muscle biopsies17' 28' 112. The abnormal intracellular 
amino-acid pattern in the ure mic muscle24 may indicate defective transport of amino-
acids over cell membranes and several abnormalities of intracellular enzyme activity have 
been found18'74'150. It is also likely that secondary consequences of uremia such as mal­
nutrition and other permissive abnormalities, contribute to the development of clinical 
uremic toxicity. 
Stageing of uremia 
There is still no general agreement on the nomenclature for the different stages of renal 
failure but we have used the following principles. During the development o f renal dis­
ease there is usually a period of varying length during which the metabolic consequences 
of impaired renal function can readily be demonst rated by laboratory methods although 
the patient remains virtually free from symptoms. This stage has often been described as 
azotemia, implying a rentention of nitrogenous metabolites in the blood. 
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When the glomerular filtration (GFR) has decreased below 15—20 ml/min the first clini­
cal symptoms of renal failure usually appear, such as gastrointestinal symptoms, fatigue 
and itching. By this time the patient has reached the stage of uremia. This stage can 
further be divided according to severity. When GFR has decreased to 2 — 3 ml/min symp­
toms of severe uremic intoxication, such as metabolic acidosis, encephalopathy and peri­
pheral neuropathy, hyperkalemia, oliguria with oedema and pericarditis, generally de­
velop. This stage is called terminal uremia, implying that the patient will no longer sur­
vive unless immediate replacement therapy, dialysis or transplantation, is started. 
The rate at which the patient will go through the different stages of renal failure depends 
above all on the rate of GFR decrease. 
Conservative treatment of uremia 
In many patients the time between first appearance of uremic symptoms and terminal 
uremia can be counted in months or even years. During this interval therapeutic measures 
can be taken that may drastically improve the patient's situation. These measures are 
often summarized under the heading conservative treatment of uremia, as opposed to ac­
tive treatment i.e. dialysis and transplantation. 
The aim of the treatment is to improve the general condition of the patient and prepare 
him for future dialysis and transplantation. The main objectives of the t reatment are 
1) to correct fluid and electrolyte balance and acidosis; 2) to reduce accumulation of 
nitrogenous metabolites in part reflected by serum urea; 3) to improve nutrition and 
counteract catabolism; and 4) to treat complicating conditions that aggravate renal fail­
ure, such as urinary tract infections or obstruction. 
Points 2 and 3 can be achieved by dietary treatment. There is long-term evidence to show 
that reduction of protein intake leads to improvement of several symptoms of uremia 
and to reduced accumulation of urea. The dilemma is how to achieve a balance between 
the aim of reducing toxicity by strict protein reduction and the risk for development of 
protein malnutrition during prolonged treatment. 
Modern dietary treatment of uremia was started in 1963, when Giordano70 demonstrated 
that endogenous urea could be utilized for protein synthesis in uremic patients on low-
protein diet. Based on these results Giovannetti and Maggiore71 demonstrated that nitro­
gen balance c ould be achieved with a diet containing only 20 g protein of high biological 
value and the "Giordano-Giovannetti diet" was created for treatment of uremic pa­
tients144 . Long-term difficulties were, however, encountered (bleeding tendency, poly­
neuropathy and pericarditis)27'100'101. 
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It was realized not only that the requirements of essential amino-acids may be greater in 
uremia than can be met by the 20 g diet, but also that the to tal amount of nitrogen sup­
plied was often too low98'100. Thus the 20 g diet had to be supplemented with essential 
amino-acids19'23'98' 100. Moreover, histidine was shown to be an essential amino-acid in 
uremia21. 
An alternative supplementation has became available with the introduction of keto-ana-
logues for five of the essential amino-acids160, permitting a total nitrogen intake of only 
4 g with maintained nitrogen balance. 
With the supplemented 20 g protein diet and a total nitrogen intake of 4.5 — 6 g/day a 
positive nitrogen balance could be achieved and satisfactory long-term clinical results 
were demonstrated without development of malnutrition or neuropathy23'2S'121'122. 
However, it has been argued that this severe protein reduction might imply a risk for a 
continuous but slow development of protein malnutrition, and that patients with uremic 
symptoms should be treated with a more moderate reduction of protein54' 97',62' 169. 
In short term studies, treatment with 40 g protein of high biological value has given 
equally good results with respect to nitrogen balance as the amino-acid-supplemented 
20 g diet96 but it has also been found that several patients on a 40 g protein diet had a 
negative nitrogen balance unless the diet was supplemented with essential amino-acids 
and histidine69'168. 
The protein requirement of uremic patients is not known and is undoubtedly variable 
depending on pretreatment condition, age, energy need and also the amino-acid compo­
sition of the proteins and the supplementation. 
The question of recycling of non-protein nitrogen has been the subject of considerable 
discussion since Giordano 70 and later Josephson94 and Richards133 demonstrated that 
labelled urea nitrogen was incorporated into body protein. Urea, degraded by bacterial 
urease to ammonia in the gut, can be reabsorbe d. In hea lthy individuals this nitrogen re­
cycling is presumably small in magnitude but it may be significant in uremia or during 
low protein intake132 . Recycling of urea may even be less important than reutilization 
of nitrogen by increased transamination prior to urea formation131'132. 
Principles of dietary treatment 
The diet and the supplementation should provide sufficient amounts of non-essential and 
essential amino-acids and energy to maintain nitrogen balance without increase in the ac­
cumulation of nitrogenous metabolites thought to be of importance for uremic toxicity. 
In the a bsence of clinically applicable objective indices for assessing uremic toxicity, mo­
nitoring of urea levels and GFR seems to be the best guide. 
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A 20 g protein diet can be made varied, palatable and convenient. The protein sources 
are mainly meat, fish and eggs and the vegetable protein amounts to only a few grams. 
This means that the dietary protein has a high biological value. The energy requirement 
is met with protein-free bread and pasta products, together with a liberal use of fat, 
sucrose and hydrolyzed com starch solutions. The diet has to be supplemented with vit­
amins and minerals. 
The supplemental amino-acids have to be administered in coated tablets to conceal their 
obnoxious taste and the large amounts of tablets needed may sometimes cause practical 
problems for the patient. 
Evaluation of long-term dietary treatment 
The long-term results should be viewed not only isolated but also in the context of the 
results of dialysis treatment. In addition to the uremic neuropathy25 and renal osteodys­
trophy7, malnutrition and rapid development of atherosclerotic vascular disease may 
emerge as major problems and a suitable dietary treatment should not lead to develop­
ment of such complications. As a background to the study to be presented, certain prin­
ciples will be reviewed. 
Assessment of nutritional status 
Routine clinical methods145 can not always be used in uremia. Body weight may fluctu­
ate owing to variations in hydration. Low molecular weight proteins or metabolites may 
accumulate owing to impaired renal excretion. Tests of immunological function may be 
influenced by the uremia itself, without relation to nutrition. Among possible methods 
for assessment of nutritional status, the following three may be considered. 
Nitrogen balance techniques: The validity of nitrogen balance studies is above all deter­
mined by the accuracy in determining nitrogen losses91. It is dependent on the patient's 
cooperation and requires hospitalization, which creates an a rtificial setting with for ex­
ample, a reduction of the patient's physical activity in most cases. Furthermore, the nitro­
gen balance technique is not suitable for long-term studies. 
Body composition determinations have advantages for long-term studies, particularly re­
peated determinations of body potassium and body water. However, calculations of body 
cell mass (BCM) from exchangeable potassium (42K) involve uncertainties of isotope 
equilibration36 which can be avoided by the use of a whole-body counter measuring the 
naturally occurring 40K emission. Furthermore, the relationships between total body po­
tassium and total body water and BCM, extracellular water and body fat may be differ­
ent from normal, owing to the abnormalities of intracellular composition in uremia 
(paper III). 
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Taking these problems into account, estimation of BCM may nevertheless have great ad­
vantages for determination of nutritional status, since it can be carried out with good pre­
cision, is atraumatic and causes little inconvenience to the patient. However, only the net 
changes in BCM are determ ined, not the relative contribution of protein synthesis and 
breakdown. 
Measurements of plasma proteins, plasma amino-acids and intracellular amino-acids: 
Serum protein determinations are simple but the important problem is still to define 
which proteins that reflect nutritional status but are not influenced by a reduced GFR". 
Several proteins with rather rapid turnover have been investigated e.g. transferrin, retinol-
binding protein, prealbumin and complement factors84'139'163'168. 
Transferrin levels are usually reduced in uremia and tend to improve with intensified nu­
trition84' 121 '163. However, the reduction of transferrin is present long before uremic 
symptoms appear with a rather moderate reduction of GFR125, and is probably not re­
lated to nutrition. Furthermore, transferrin levels are influenced by the iron status of the 
patient. 
Plasma amino-acid levels and especially relationships between certain essential and non­
essential amino-acids, such as the valine/glycine ratio, may reflect acute nutritional defi­
ciencies but are also influenced by the preceding meal". The intracellular amino-acid 
pattern, as demonstrated in muscle biopsies, has been found to be abnormal in uremia, 
with a reduction of essential amino-acids not parallel to the changes in plasma24. Treat­
ment with essential amino-acids has been found to improve the intracellular amino-acid 
pattern24. 
Development of atherosclerotic vascular disease 
Treatment of uremia with dialysis and also with transplantation has been linked to an ac­
celerated development of atherosclerotic vascular disease. Long-term observations8'107  
have indicated cardiovascular disease to be the m ost important complication of treatment 
of uremia with respect to survival. 
Several of t he risk factors for development of atherosclerosis e.g. hypertension, platelet 
dysfunction, hyperuricemia, hyperparathyreoidism and particularly disturbances of lipid 
and carbohydrate metabolism, are present in uremia74. The dietary treatment could have 
negative influence on these disturbances of lipid and carbohydrate metabolism and as­
sessment of such an influence therefore seems to be of significant interest. 
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Lipid and carbohydrate metabolism 
Serum lipids are transported together with specific proteins (apolipoproteins) as lipopro­
teins. Based on differences in density, the lipoproteins can be described by a density 
spectrum which in turn is related to the relative amount of their components. They can 
be classified as high-density lipoproteins (HDL), low-density lipoproteins (LDL), very-
low-density lipoproteins (VLDL) and chylomicrons (Fig. 1). Lipoproteins can also be 
classified according to their electrophoretic mobility into a-lipoproteins, pre-ß-lipopro-
teins, ^-lipoproteins and chylomicrons. The difference in mobility is determined by the 
presence of different apolipoproteins on the lipoprotein surface. 
Density g/ml 0.92 
Sf. 
0.96 1.006 1.063 1.21 135 
1 
Chylomicron 400 VLDL 
1 
20 LDL 
1 
0 HDL 
0 Preß-Lp 1 |3-Lp ! oi-Lp Albumin 
Major apo- g 
lipoproteins 
LIVER 
GLYCEROL 
MUSCLE 
ADIPOSE 
T 
•CD CD 
CH 
V LCAT/ 
OCZXZ!) TISSUE 
BLOOD 
Fig. 1. Lipoprotein spectrum and metabolism with schematicalpresentation according to 
density classes, electrophoretic mobility and distribution of major apolipoproteins. 
(VLDL = very low density lipoproteins, LDL = low density lipoproteins, HDL = high 
density lipoproteins, Lp = lipoproteins, LCAT = lecithin: cholesterolacyl transferase, TG 
= triglycerides, CH = cholesterol, FFA = non-esterified fatty acids). 
So far three major apolipoproteins have been identified:— apolipoprotein A (apo—A), 
apolipoprotein B (apo—B) and apolipoprotein C (apo—C) — in addition to four minor 
apolipoproteins. These apolipoproteins are in turn characterized by their constitutive 
polypeptides, apo—Aj and apo—AJJ, apo—B (presumably composed of two non-identical 
polypeptides) and apo—Cj, —CJJ and CJJJ. 
Apart from having a function in lipid transport, these apolipoproteins also participate as 
activators or inhibitors of enzymes in lipoprotein catabolism58' 73. 
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Lipoprotein metabolism 
Dietary fat, primarily triglycerides (TG), is transported together with small amounts of 
cholesterol and protein in chylomicrons from the intestine to the general circulation. The 
nascent chylomicron contains apo—B and apo—A from the intestinal cell as its protein 
moiety and receives additional apo—C from HDL when entering the circulation82. The 
load of TG is hydrolysed by lipoprotein lipase to free fatty acids (FFA) and glycerol. 
FFA can be reassembled with locally synthesized glycerol to TG and stored in the adi­
pose tissue or be utilized in peripheral tissues for energy production. 
About 20 g of TG is formed daily in the liver and released to the circulation as VLDL— 
TG. TG production is regulated by availability of substrate — FFA preferentially released 
by lipolysis in adipose tissue and glycerol from glucose through the action of a-glycero-
phosphate and with insulin as a prerequisite. 
VLDL are catabolized, in analogy with the chylomicrons, to glyceril and FFA by the ac­
tion of lipoprotein lipase. This transformation is also accompanied by the return of apo-
C and surface lipids to HDL where the lipids form the substrate for the lecithin: chole­
sterol acyl transferase (LCAT)-reaction57'58. 
LDL, the major cholesterol-carrying lipoprotein, is catabolized after internalization in 
various peripheral cell systems. The liberated cholesterol is partly utilized for membrane 
synthesis. The internalization requires specific LDL receptors on the cell surface. Familial 
hypercholesterolemia is characterized by a defect in these LDL receptors37. The liberated 
intracellular cholesterol is subsequently taken up by HDL in a centripetal cholesterol 
transport57'104. 
HDL is possibly formed in the intestine and liver58'82 and its major protein moiety is 
apo—A1 6 6 .  HDL serves as a  donator of  the l ipase-activating peptides,  apo— Cj and —CJJ,  
and as a p latform for cholesterol esterification by LCAT. The major portion of HDL 
cholesterol esters presumably returns to the liver in the centripetal cholesterol transport 
to be catabolized to bile acids104. 
Fatty acids 
Fatty acids are components for several lipids e.g. TG, cholesterol ester and phospholipids, 
and also appear as albumin-bound free fatty acids (FFA). 
The fatty acids may be saturated or unsaturated, essential or non-essential (Table I). The 
primary essential fatty acid in humans has been found to be linoleic (18:2) acid in the 
(n — 6) series89, from which arachidonic (20:4) acid can be synthesized. When lipolysis in 
adipose tissue is increased the excess FFA is utilized in the liver for glucose or TG pro­
duction, which may cause an increase in VLDL production and release into the blood. 
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Name Carbon atoms 
and double bonds 
Saturated 
Unsaturated 
non-essential 
Unsaturated 
essential 
palmitic acid 16:0 
stearic acid 18:0 
palmitoleic 16:1 (n--7) 
oleic acid 18:1 (n-~9) 
linolenic acid 18:3 (n--3) 
linoleic acid 18:2 (n--6) 
arachidonic acid 20:4 (n--6) 
Table I. Some important naturally occurring fatty acids 
Phospholipids 
Phospholipids are present in serum lipoproteins and cell membranes and lecithin is the 
major (70 %) phospholipid in human serum. Lecithin is synthesized in the liver along 
two major pathways (Fig. 2). Pathway I (Kennedy pathway) is quantitatively most im­
portant, yielding palmitic (16:0) acid in the 1-position and linoleic (18:2) or oleic (18:1) 
acid in the 2-position14. A decrease of this synthesis pathway is seen in man after sucrose 
feeding1 while an increase was observed after administration of linoleic acid148 . Pathway 
II (Greenberg pathway) preferably gives stearic (18:0) acid in the 1-position and arachid-
onic (20:4) acid or other polyunsaturated fatty acids (e.g. 22:6) in the 2-position. This 
pathway appears to be more active in females and under the influence of estrogen93. In­
fluences on one lecithin synthesis pathway appear to cause reciprocal changes in the 
other. 
LECITHIN SYNTHESIS 
18:2/18:1 
— P-choline 
Diglyceride 
0 
20:4/22:6 3»CH3 Me thionine, 
P-ethanolamine 
—16X1 
—18-2/18.1 
/CH3 
P-0-(CH2)2N-CH3 
Lecithin XCH3 
Triglyceride 
—18.0 
20:4/22:6 
/CH3 
P-0~(CH2)2N-CH3 
Lecithin ^CH3 
PATHWAY I 
Fig. 2. Major pathways of liver lecithin synthesis. Pathway I (Kennedy pathway): Cyti-
dine-diphosphate (CDP) — choline diglyceride pathway. Pathway II (Greenberg pathway): 
Cytidine-diphosphate (CDP) ethanolamine methylation pathway. 
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Lecithin cholesterolacyl transferase (LCAT) 
In human serum about 70 per cent of cholesterol is in esterified form and 30 per cent is 
unesterified. Esterification of cholesterol in plasma is mediated by the enzyme LCAT, 
synthesized in the liver and carried with HDL72'158. The fatty acid in the 2-position of 
lecithin is transferred to the 3-position of cholesterol (Fig. 3). This reaction is influenced 
by the fatty acid composition of lecithin, with linoleic (18:2) acid as a preferred sub­
strate143. Decreased availability of the preferred substrate in LCAT might result in im­
paired removal of VLDL148. 
LCAT react ion 
LCAT 
P-choline 
Lecithin + free  choles terol  *" Lysoleci thin + cholesterol  ester  
Fig. 3. LCAT-reaction. The enzyme lecithin: cholesterol acyl transferase (LCAT) catalyzes 
in serum the transfer of fatty acid in 2-position of lecithin into 3-position of cholesterol. 
16:0 = palmitic acid, 18:2 = linoleic acid. 
Lipoprotein lipase (LPL) 
TG removal from VLDL and chylomicrons occurs in the capillary bed of most tissues by 
hydrolysis of TG through the action of the LPL system. Heparin and other polyvalent 
anions can liberate LPL from the tissues into the circulation and it can then be measured 
as postheparin lipolytic activity (PHLA). In postheparin plasma at least two56'76 or 
three68 different lipase systems have been demonstrated. One (or two) of them is LPL 
activity and the other is called hepatic triglyceride lipase (HTG) or salt-resistant lipase. 
Apo~CJ and —CJJ have been fou nd to be essential activators for LPL hydrolysis of chylo­
microns and VLDL—TG68. C[ and CJJ are presumably recirculated from VLDL to HDL. 
LPL is stimulated by insulin and also by other hormonal influences and nutritional sta­
tus40 . Both low40' 68'76'128 and normal118 activity of PHLA or adipose tissue lipopro­
tein lipase have been fou nd in hypertriglyceridemia. 
The function of the HTG has been suggested to be in the further conversion of interme­
diate low density lipoproteins (ILDL) or remnant lipoproteins to LDL76'113. Reduced 
activity of the HTG has been detected during estrogen administration4 while androgens 
seems to increase the activity of this enzyme55. 
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Intermediary metabolism 
Protein, lipid and carbohydrate metabolism are closely linked to one another at several 
levels in the intermediary metabolism particularly in relation to gluconeogenesis and glu­
cose utilization. 
From glucose can be derived glycerol, via »-glycerophosphate, fatty acids, via acetyl-CoA 
and beta-oxidation and the carbon skeletons for amino-acids, via puruvate and lactate. 
Glucose can be formed from glycerol, the carbon skeletons of amino-acids, via puruvate 
and oxaloacetate and from lactate. 
Transport of lipids is dependent on protein metabolism for synthesis of apolipoproteins, 
LCAT and LPL. 
During metabolic stress from different causes, such as chronic disease, e.g. uremia, star­
vation or protein depletion, these interrelationships become more apparent12' 44. During 
low protein intake adaptive changes occur in t he intermediate metabolism to preserve 
protein in t he organism147. These adaptations are, however, dependent on the availability 
of carbohydrate and fat for energy production44'147. Amino-acid-conserving enzymes in­
crease their activity and nitrogen excretion is reduced110'133. Insulin acts as an anabolic 
hormone in the preservation of the structural integrity of the cell. When, on the other 
hand, the energy supplies are insufficient, owing to e.g. anorexia, amino-acids are more 
readily catabolized for energy production and the formation of urea and other nitrogen­
ous metabolites increases. With impaired renal function this catabolism causes a rapid ac­
cumulation of non-protein nitrogen, as indicated by elevated serum urea levels. 
AIMS OF THE STUDY 
In view of the problems outlined in the introduction it was thought to be of interest to 
investigate the effect of dietary treatment in ure mia, with the following specific objec­
tives: 
1. To find a method for functional classification of patients by accurate determination 
of glomerular filtration rate (GFR) in renal insufficiency and to evaluate the limitations 
of GFR for successful dietary treatment. 
2. To evaluate the amount of essential amino-acid supplementation to a 20 g protein diet 
necessary to maintain nitrogen balance. 
3. To study to which extent the dietary treatment can maintain the body composition 
during long-term treatment. 
4. To investigate lipid and carbohydrate metabolism in patients with uremia and the in­
fluence of dietary treatment. 
5. To study the adherence to the diet during long-term treatment in uremic patients. 
14 
PATIENT SERIES AND MANAGEMENT OF PATIENTS 
The different patient series were collected from among about 150 consecutive patients 
with uremia treated with protein-reduced diet at Sahlgrenska sjukhuset during 1970 — 
1978. 
Certain patients were included in more than one series, as demonstrated in Fig. 4. The 
total number of individuals studied was 80 (55 men and 25 women, aged 18 — 71 years). 
Selection of patients for study was determined by availability of investigation, ward and 
staff capacity and by the patient's willingness to participate. Patients with terminal ure­
mia, oliguria, severe heart disease or other conditions rendering them inaccessible for 
long-term treatment were excluded. 
UREMIC PATIENTS 
ON DIETARY 
. TREATMENT y 
SERIES I 
SERIES nn 
n = 49 
SERIES 
SERIES I Fig. 4. Patient series I — IV. 
(n = number of patients). 
Patient series I (May 1975 to June 1976). Renal function studies (Paper I). 
Fifteen patients (10 men and 5 women, mean age 46 years) were investigated before treat­
ment and nine of these patients were examined at three-month intervals during treat­
ment. In addition, two anephric women on dialysis were studied between two dialysis 
sessions. 
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Patient series II (February 1970 to November 1971). Nitrogen balance 
studies (Paper II). 
Seventeen consecutive patients (10 men and 7 women, mean age 48 years) were selected 
for this study. Results from only 14 of these patients will be reported since three patients 
were started on nitrogen balance studies but had to be withdrawn because of rapidly de­
veloping terminal uremia, with severe gastrointestinal symptoms, overhydration and im­
mediate need for dialysis. Clinical details of the 14 patients are shown in Table I, paper II. 
Patient series III (September 1974 to March 1977). Body composition 
studies (Paper III). 
Altogether 49 patients (37 men and 12 women, mean age 45 years) were studied, 38 of 
whom (30 men and 8 women) were investigated immediately before the start of dietary 
treatment. Twenty of the patients were followed during treatment. Thirteen of the re­
maining 18 patients had to be withdrawn for various reasons (dialysis 9, transplantation 
2 and refusal to participate 2 patients), 3 patients died early and 2 patients had not par­
ticipated for more than two months when the study was terminated. Eleven additional 
patients (7 men and 4 women), who started treatment before facilities for whole-body 
counting became available were studied during treatment alone. Thus 31 patients were 
examined at three-month intervals during treatment for 3 — 12 months (mean 9.2 
months). 
Patient series IV (June 1975 to March 1978). Lipid and carbohydrate meta­
bolism (Paper IV — V). 
Twenty-eight consecutive patients (20 men and 8 women, mean age 47 years) were in­
vestigated before the start of dietary treatment (Series IV A, paper IV). 
In addition, 7 patients (5 men and 2 women) participated in certain investigations of 
lipid metabolism. 
Six out of the 28 patients in series IV A did not complete three months' treatment, while 
22 patients (16 men and 6 women, mean age 45 years) were investigated every three 
months during treatment for on average 9.1 months (series IV B, paper V). 
Management of patients 
All pati ents had the accepted indications for treatment with protein-reduced diet i.e. 
chronic irreversible renal failure with uremic symptoms. Most of the patients had mild to 
moderate clinical manifestations of uremia, such as gastrointestinal symptoms with ano­
rexia, nausea and occasional vomiting, pruritus and fatigue. No patient had evidence of 
severe renal osteodystrophy or neuropathy. 
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The patients were admitted to the renal ward for initiation of dietary treatment and cor­
rection of disturbances in fluid and electrolyte balance and metabolic acidosis, as appro­
priate. Initially, the patients were given detoxification treatment with the 20 g protein 
diet only or in a very few cases, intravenous glucose and fat until oral nutrition could be 
started. 
After 6 — 10 days an improvement of symptoms was generally observed together with a 
decrease of the serum urea level. Supplementation of the diet with the essential amino-
acids and histidine (EA.AH) was then started and the patients were discharged from the 
hospital shortly thereafter. The patients were then controlled at a special outpatient 
dietary clinic. The patients in series IV B were readmitted to the hospital for 3 — 4 days 
every three months for metabolic studies. 
Duration of treatment (Fig. 5) 
50 % of the patients were treated for 6 months and 25 % for 12 months. Forty-six of the 
80 patients were put on hemodialysis treatment after on average 9.0 months, when the 
uremic symptoms could no longer be controlled by the dietary treatment. Thirteen pa­
tients were transplanted after on average 7.3 months without previous dialysis. Ten pa­
tients who were considered unsuitable for dialysis died from uremia after on average 7.1 
months, while 2 patients died from myocardial infarction and septicemia respectively. 
Eight patients were still on dietary treatment (mean duration 8.1 months) at the end of 
the investigation (March 1978). In one patient with primary amyloidosis dietary treat­
ment was withdrawn after 18 months owing to improvement of renal function. 
No of patients 
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Months on diet 
Fig. 5. Duration of dietary treatment in 80 patients with uremia (series I - IV). 
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Dietary treatment 
Dietary counselling was given to all patients by the same dietitian. The patients were also 
given thorough information by the physician about the principles and aims of the treat­
ment. After taking a dietary history, the dietitian gave individualized counselling to the 
patient and to his or her spouse in several sessions. The normal food habits of each pa­
tient and his family were as far as possible adapted to the dietary principles. The patients 
were also provided with a special cookery book for uremic patients164. 
After discharge from hospital the patients were seen at the outpatient dietary clinic by 
the author and the same dietitian, who collaborated to achieve the best possible dietary 
adherence and patient education. 
Composition of the diet (Series III and IV) 
The diet was based on a varied four-week menu164, and an average daily protein intake 
of 20 g from varied sources was prescribed together with an energy content of 35 — 45 
kcal (150 — 190 k J)/kg BW. Energy was mainly supplied from dairy fat (butter, double 
cream) and protein-free bread, pasta products, sweet preserves etc. When necessary, a 
partially hydrolyzed corn starch solution (Trilgar®) was added. 
Dietary adherence 
In order to study the patient's adherence to the diet and to provide a basis for the study 
of the influence of diet on lipid and carbohydrate metabolism, four-day records of food 
intake were collected at three-month intervals from 19 patients in series IV B. 
Since the dietary principles and counselling were identical for the patients in series III 
and IV, the results were considered generally representative for our patients on dietary 
treatment with the 20 g protein diet and EAAH. 
The patients recorded, after receiving detailed instructions, their food intake during the 
four days (Wednesday - Saturday) preceding their follow-up admission to the hospital. 
The records were checked and completed by the dietitian with the help of the patient. 
Food tables were used for calculation of the daily intake of energy, protein, fat, carbo­
hydrate and sucrose and for estimation of the ratio of polyunsaturated to saturated fatty 
acids (P/S). The records from two patients were incomplete and omitted while the records 
from 1 7 patients, covering in all 204 days could be evaluated (Table II). 
The dietary content of essential amino-acids (EAA) could be c alculated for on average 
70 % of the protein intake. Assuming the same proportions of EAA in the remaining 30 % 
the mean calculated daily intake of EAA from the food was 8.0 g, corresponding to a 
mean E/T ratio of 2.3. The daily intake of individual amino-acids, expressed in per cent 
of the minimum requirement134, is shown in Fig . 6. 
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Energy Protein Carbo- Sucrose Fat p/s-ratio 
kcal (kJ) hydrate 
mean 
SD 
per kg BW 
mean 
2403 
(10100) 
542 
(2280) 
35 
(150) 
20.3 
2.8 
0.3 
291 
93 
4.2 
99 
44 
1.4 
125 0.34 
25 0.09 
1.8 
Table II. Calculated daily food intake in 17 patients with uremia on a protein-reduced 
diet. Mean values are derived fro m averages of 1 — 6 four-day records per patient. 
Sucrose content could be calculated for 92 % of dietary carbohydrate and ratio of 
polyunsaturated to saturated fat (p/s-ratio ) for 88 % of dietary fat. 
<ya of minimum requirement 
250 
200. 
150. 
100. 
50. 
rf rh 
Fig. 6. Average daily content of the essential amino-acids and histidine in the 20 g pro­
tein diet. The content of amino-acids is expressed as per cent (mean ± SD ) of minimum 
requirement134. 
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In 13 patients records from two or more registration periods were available and the con­
stancy of dietary adherence could be estimated. The mean difference in per cent (± SD) 
of registered intake between the first four-day record and a subsequent record was for: 
Energy 10.1 ±7.1% Carbohydrate 16.5 ±13.0% 
Protein 9.7 ± 5.9 % Sucrose 25.9 ± 27.7 % 
Fat 12.7 ±6.9% P/S ratio 26.3 + 17.0% 
Supplementation with essential amino-acids and histidine (EAAH) 
The EAAH were given in coated, tasteless tablets or (Series I) by i.v. infusion (Aminess®, 
AB Vitrum, Stockholm, Sweden). 
Fifteen tablets or 200 ml of infusion solution contained: 
g gN 
L—isoleucine 1.15 0.12 
L—leucine 1.65 0.16 
L—lysine acetate (1.70) 
eq. lysine 1.20 0.23 
L—methionine 1.65 0.15 
L—phenylalanine 1.65 0.14 
L—threonine 0.75 0.09 
L—tryptophan 0.38 0.05 
L—valine 1.20 0.14 
L—histidine 0.83 0.23 
10.46 1.31 
The above dose corresponds to 1.5 times the minimum requirement for the essential 
amino-acids according to Rose134. 
Orally, 5 tablets were given three times a day at mealtimes, while the patients on i.v. sub­
stitution received 200 or 400 ml, as described in detail in paper II. 
Medication 
The diet was routinely supplemented by 1 — 2 iron and multivitamin tablets daily (Duro-
feron vitamin®, AB Hässle, Göteborg, Sweden). Sodium bicarbonate, 3-6 g/day, was 
prescribed for all but a few patients. Fluid retention, hypertension and cardiac insuffi­
ciency were treated when necessary with appropriate drugs (furosemide, hydralazine, 
propranolol, alprenolol, Clonidine, digitoxin). No patient received corticosteroids or cyto­
toxic drugs except for two patients in series III, who were maintained on 5 mg of predni­
solone daily. 
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Statistical methods 
To describe data means and standard deviations have been used. To evaluate the effect 
of treatment or to compare groups of patients, Student's t-test was used either on orig­
inal variables, assuming a normal distribution of the observations, or on transformed 
variables. Thus measurements of lipid variables have been subjected to a logarithmic 
transformation, due to apparent skewness observed in other materials. Non-parametric 
methods have been used in other parts of the study. Correlations have been computed 
with Spearman's rank correlation method. Values of p < 0.05 were considered significant. 
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METHODS AND RESULTS 
Except where otherwise specified, the following methods were used in the different pa­
tient series. Creatinine was determined by an a lkaline picrate method85, without precipi­
tation, adapted for automatic analysis (Vickers M300). The serum urea concentration 
was determined with a Technicon Autoanalyzer (method NI C). The serum albumin con­
centration was measured by a bromocresol green-binding method using Albustrate® with 
measurement of absorbance 15 s after mixing reagent and serum. Serum iron and total 
iron binding capacity (TIBC), as a measure of transferrin, was determined according to 
Zak and Epstein170. From April 1977, however, ferrozine was used as chelator instead of 
bathophenantroline. The serum concentrations of creatinine, urea, albumin and TIBC 
were determined by the Department of Clinical Chemistry, University of Göteborg, at 
this hospital. 
Determination of the glomerular filtration rate (GFR). Series I (Paper I). 
Methods 
Glomerular filtration rate (GFR) was determined by conventional clearance technique 
with collection of urine without indwelling catheters and measurement of plasma and 
urine concentration of the filtration markers (endogenous creatinine, inulin and 51 Cr— 
EDTA) - henceforth called renal clearance and calculated from the 160 min clearance 
of creatinine, inulin and 51Cr-EDTA and 24 h clearance of creatinine and slCr-EDTA. 
Clearance of slCr-EDTA was also calculated by determination of the plasma elimination 
curve after single injection of the marker - henceforth called plasma clearance. The 
clearance value was obtained from the general formula Q = D/A, where D is the dose of 
the marker injected and A the area under the plasma elimination curve. 
160 min GFR determinations were done in the morning during four periods of 40 min 
duration. Collection of urine began 40 min after i.v. administration of inulin (Inutest® 
0.2 ml/kg BW of 25 % solution) and 51 Cr-EDTA (50 - 200 pCi, Behringwerke AG). 
Blood samples were drawn 60, 100, 140 and 180 min after injection of the marker i.e. in 
the middle of each clearance period. The average diuresis was 2 — 5 ml/min i.e. about 
50% of GFR. 
The renal 24 h clearance (creatinine and 51Cr—EDTA) was determined during the 4 — 
28 h following the injection of 51 Cr—EDTA. The clearance was determined from the 
plasma creatinine concentration at the beginning of the clearance period and from the 
mean 51 Cr—EDTA concentration. 
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Plasma clearance of 51Cr—EDTA was determined 3 — 4 h and 4 — 28 h after injection 
with plasma sampling at 180, 200, 220 and 240 min and 24 h after injection of the mar­
ker. Clearance was calculated from the dose of51 Cr—EDTA and the plasma elimination 
curve, as described by Brochner-Mortensen41. 
Inulin was determined with blank correction as described in paper 1.51 Cr—EDTA was 
determined in a well scintillation counter with 3 ml sample volume and 30 min counting 
time. 
GFR during dietary treatment: GER was also determined from the 160 min 51 Cr—EDTA 
renal clearance every three months during dietary treatment in 24 patients from series 
III and IV. 
Results 
Determination of GFR: Renal inulin clearance ( 160 min) was chosen as the reference de­
termination of GFR. 
Renal slCr-EDTA clearance ( 160 min) (Fig. 7) was closely correlated to inulin clearance, 
without systematic deviation. 
RENAL INULIN CLEARANCE (160 min) ml/min 
Fig. 7. Correlation between renal51 Cr— 
EDTA clearance (160 min) and renal inu­
lin clearance ( 160 min). 
15 
10 
1
—
J r 
UJ 5 
o ' 
RENAL Cr-EDTA CLEARANCE (160 min) ml/min 
Fig. 8. Correlation between plasma clear­
ance (5JI 4 h) and renal clearance (160 
min) of51 Cr -EDTA. 
Plasma slCr-EDTA clearance (2 - 4 h) (Fig. 8) overestimated GFR by on average 4.2 
ml/min in the range 2.6 - 11.2 ml/min. Plasma clearance ofS1 Cr—EDTA was, however, 
better correlated t o the renal clearance when studied during the 4 - 28 h after injection 
of the marker (Fig. 7, paper I). 
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Serum creatinine was poorly correlated to GFR (Fig. 2, paper I) and renal creatinine 
clearance ( 160 min) overestimated GFR by on average 30 per cent (Fig. 3, paper I). 
Renal clearances of creatinine and slCr~EDTA (24 h) were poorly correlated to the cor­
responding 160 min renal clearances, giving on average 37 per cent lower values (Fig. 5, 
paper I). 
Plasma slCr-EDTA clearance in anephric patients (Table I, paper I). Calculations of the 
elimination of the marker 16 - 20 h after injection indicated an extrarenal clearance of 
approximately 2 ml/min. 
GFR during dietary treatment 
There was a continuous decrease of GFR during treatment (Fig. 9). The mean GFR was 
7.8 ± 2.5 (SD) ml/min at the start of treatment and it is apparent that only a few patients 
with GFR < 4 ml/min remained on treatment for three months or longer. Furthermore, 
patients with GFR < 4 ml/min at the start did not complete 3 months' treatment. 
G F R  
m l / m i n  
;16.2 
18  mo n ths  
Fig. 9. Glomerular filtration rate (GFR), measured from the renal clearance (160 min) 
ofslCr—EDTA, in 24 patients with uremia during dietary treatment. Symbols (D = dia­
lysis, Tp = transplantation, f = patient death, = continued treatment) indicate status 
at the next three-month follow-up. 
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Nitrogen balance studies. Series II (Paper II). 
Methods 
After admission to the hospital, the patients received a 20 g protein diet (basic diet) 
only for 2 to 6 days, after which period supplementation with EAAJH in different dosages 
was started, generally in periods of six days, as described in detail in paper II. 
Nitrogen intake was measured by analysis of duplicate portions and left-overs during all 
but three balance studies, when the intake was calculated from food tables. Nitrogen in 
food and urine (24 h periods) was determined by micro-Kjeldahl technique using an auto-
analyzer system (Technicon methods N—3b, N38). 
Nitrogen balance was calculated as the apparent nitrogen balance i.e. the difference be­
tween nitrogen intake and nitrogen excretion in the urine. The mean daily apparent 
nitrogen balance was derived from the whole balance period. 
The corrected apparent nitrogen balance was estimated taking into account changes in 
serum urea and estimations of total body water140. This correction of nitrogen balance is 
greatly influenced by the accuracy of the serum urea determinations. True and false day-
to-day variations of only a few mmol/1 are common and imply corrections by as much as 
0.5 — 1 gN/day, which is highly significant within the nitrogen balance range studied. 
In order to minimize these possible errors, the mean daily change in total urea nitrogen 
for all patients during each balance period was used when estimating the mean corrected 
apparent nitrogen balance. 
Patients with only two days on basic diet were apparently not always in steady state, 
while six days were judged to be sufficient from the observations in one patient who was 
studied for 14 days during one balance period and had reached a steady state within six 
days. The mean apparent nitrogen balance was therefore weighted according to the length 
of the balance period. 
Accurate measurements of all extrarenal losses are important but very difficult to per­
form. Earlier studies23 indicate that the fecal loss of nitrogen of about 1 g N/day in 
uremia is not influenced by diet or EAAH. Accurate determinations of dermal losses of 
nitrogen in uremia have not been published but there is no reason to assume that they 
are less t han 1 g N/day estimated as a mean value in non-uremic subjects91. Extrarenal 
losses of nitrogen in uremia may thus be assumed to be about 2 g N/day. 
Results (Table III, fig. 10) 
a) Basic diet — 20 g protein (14 patients) 
All pat ients had a negative apparent nitrogen balance, mean —2.1 ± 1.3 (SD) g/24h (men 
—2.1 ± 1.7, women —2.1 ± 0.9). 
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Fig. 10. Apparent nitrogen balance in 14 patients with uremia and mean ± SE treated 
with a 20 g protein diet (basic diet) and supplementation with essential amino-acids 
and histidine (EAAH) 2.6 gN and 1.3 gN i.v. and 1.3 gN by mouth (oral). Open 
symbols = women, closed symbols = men. 
b) Intravenous supplementation of the basic diet with EAAH: 
EAAH 2.6 gN (400 ml) i.v. ( 14 balance periods in 12 patients). The apparent nitrogen 
balance was improved in all patients and was positive in 10, mean +1.4 ± 1.8 (SD) g/24 h 
(men +0.9 ± 1.9, women +2.0 ± 1.5). 
EAAH 1.3 gN (200 ml) i.v. ( 7patients). The apparent nitrogen balance was improved in 
all patients and was positive in 3 patients, mean +0.4 ±1.3 (SD) g/24 h (men +0.3 ± 
1.3, women +0.5 ± 1.5). 
c) Oral supplementation of the basic diet with EAAH 
EAAH 1.3 gN, ( 16 balance periods in 10 patients). The apparent nitrogen balance was 
improved in all pa tients and was positive during 13 periods, mean +1.2 ± 1.7 (SD) g/24 h 
(men +0.9 ± 2.0, women +1.7 ± 0.8). 
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The apparent nitrogen balance improved significantly (p = < 0.01) during all periods with 
EAAH compared to the basic diet only. The mean paired difference (n = 10) between the 
apparent nitrogen balance with 2.6 g N i.v. and 1.3 g N by mouth was 0.59 g N/24 h (p = 
0.05) while the opposite difference was found for corrected apparent nitrogen balance. 
With 1.3 g N i.v. the apparent nitrogen balance tended to be inferior to that with 2.6 g N 
1.v. (mean paired difference 2.4 g N, n = 6) and to that with 1.3 g N by mouth (mean 
paired difference 1.5 g N, n = 5) but the small number of pairs does not permit a valid 
statistical analysis of significance. 
Body composition studies. Series III (Paper III). 
Methods 
Body composition was calculated from body weight (BW), total body potassium (TBK) 
and total body water (TBW). BW and body height (BH) were measured with standardized 
technique in co nnection with the whole-body counting procedure. TBK was calculated 
from 40K measured in a sensitive 3 n-whole -body counter5. TBW was determined after an 
oral load of 100 juCi tritiated water (THO) and determination of THO by liquid scintil­
lation technique on sublimated samples of plasma after 2 h of equilibration. 
The total expected SD of a single determination was 80 mmol for TBK146 and 1.2 litres 
for TBW38. 
Control series 
The findings were compared with those in a reference g roup of 489 apparently healthy 
men (n = 134) and women (n = 355), aged 20 — 70 years, consisting of participants in 
population studies and hospital staff38. 
Comparison was made for TBK and TBW for sex and BH. 
Methodological considerations 
The calculation of body cell mass (BCM) was based upon the assumption of an intracel­
lular potassium concentration (1CK) of 150 mmol/1 intracellular water and assuming that 
3 mmol K = 1 g N = 25 g cell mass114, which assumption is supported by analysis of biop­
sies from muscle tissue representing about 70 per cent of BCM17. 
However, in uremia th ere are clear difficulties in estimating BCM from TBK as both nor­
mal and low 1CK and ratios of 1CK to intracellular protein may occur (paper III). 
In adults the reported abnormalities of intracellular composition have been less pro­
nounced than in child ren and are also either associated with low exchangeable potassium 
or found in p atients immediately before dialysis. Pending conclusive evidence of the re­
lationship between TBK and BCM in uremi c patients with normal TBK, the estimation 
of BCM was done as in the reference group. Marked overhydration was not evident in 
these patients. 
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Body composition before treatment (Table I, paper III) 
Body weight (BW): 29 out of 37 men and 8 out of 12 women had BW within or above 
SW± 10 %106. 
Total body potassium (TBK): 25 out of 30 men and 5 out of 8 women had TBK values 
within or above the mean ± 1 SD for height of the reference group (Fig. 11). 
TBK 
mmol 
6000-
4000-
3000-
2000-
155 195 BH cm 165 175 185 145 
Fig. 11. Total body potassium (TBK) and body height (BH) in 30 male patients and 8 
female patients with uremia before start of dietary treatment. Relation to mean ± SD 
for body height of control series. 
Total body water (TBW): 19 out of 28 men and 3 out of 7 women had TBW values with­
in the mean ± 1 SD for the reference group (Fig, 12). 
In all patients TBK and TBW were highly correlated to BW (r = 0.72 and 0.89, p < 0.001). 
TBK and TBW were also correlated (r = 0.83, p < 0.001). Body composition variables 
were not correlated to serum creatinine or serum urea. 
Body composition during treatment (Tables II and III, paper III) 
The results were based on observations in 31 patients with a mean duration of observation 
of 9.3 months (range 3 — 12 months), (Fig. 13). There was no significant change of BH 
adjusted mean BW or mean TBK values during treatment. 
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Ä Fig. 12. Total body water (TBW) and body 
height (BH) in 28 male patients and 7 female 
patients with uremia before start of dietary 
treatment. Relation to mean ± SD for body 
height of control series. 
I 
Fig. 13. Body weight (BW), total body 
potassium (TBK) and to tal body water (TBW) 
31 patients with uremia during treatment with 
protein-reduced diet and essential amino acids. 
Mean ± SE adjusted for differences in mean 
body height at different observation intervals. 
Figures refer to number of patients studied. 
Solid lines: men, broken lines: women. 
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In 10 out of 31 patients there was a decrease in TBK (mean 479 mmol, range 243 — 
1651) between the first and last observation. Six out of 31 patients had an increase of 
TBK (mean 352 mmol, range 231 — 530). 
Mean TBW did not change during treatment but in 10 out of 30 patients TBW decreased 
(mean 6.01, range 3 — 8.9) and in 4 out of 30 patients TBW increased (mean 6.5 1). 
There was no correlation between the changes of BW, TBK and TBW or between the 
changes and the initial values. 
Lipid and carbohydrate metabolism. Series IV (Paper IV — V). 
Methods 
Unless otherwise stated, venous blood samples were drawn in the morning, after an over­
night fast, and centrifuged at low speed. 
Serum lipids: Cholesterol was determined according to the method of Cramér and Isaks­
son49 , triglycerides (TG) according to the method of Carlson46 and phospholipids as de­
scribed by Bartlett et al.15. Non-esterified fatty acids (FFA) were determined with a 
modified Dole-procedure as used by Friedberg et al.64. 
Lipoprotein cholesterol: Very-low-density lipoproteins (VLDL) were isolated by prepara­
tive ultracentrifugation in the supernatant at density (D) 1.006 g/ml as described in 
paper IV. 
Cholesterol content of a-lipoproteins (a-Lp) was determined in whole serum after the 
elimin ation of VLDL and LDL by precipitation with heparin and manganese chloride43. 
LDL cholesterol was estimated as the difference between cholesterol content of infra-
natant at density 1.006 g/ml and a-lipoprotein cholesterol. 
The methodological errors were 3 % for serum cholesterol, 4 % for TG, 5 % for phospho­
lipids and 4 % for a—Lp cholesterol. 
Lipoprotein electrophoresis was performed on agarose gel as described by Gustafson et 
al.79. 
An intravenous fat tolerance test (IVFTT) with Intralipid® (AB Vitrum, Stockholm, 
Sweden) described by Carlson and Rössner47, was performed in a subsample (n = 13), as 
described in paper IV. The disappearance rate (k2) of Intralipid turbidity was expressed 
as the slope of the disappearance curve (per cent/min). 
Lecithin: cholesterol acyl transferase activity (LCAT) was determined in 17 patients (14 
men, 3 women) before treatment and at 3 (n = 10), 6 (n = 6) and T (n = 5) months. 
LCAT was determined with a modified Stokke-Norum method159' 166 and expressed as 
Mmol esterified cholesterol (CE)l/h. The error of the method was 3 %. 
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Relative fatty acid composition of lecithin was determined by gas liquid chromatography 
(GLC) in 24 patients before the start of treatment and at 6 (n = 14), 12 (n = 9) and T 
(n = 16) months. 
Preparation of lipids and lecithin fatty acid methyl esters: Separation of lipids was done 
by thin-layer chromatography on Silica gel. Preparation of fatty acid methyl esters was 
performed for lecithin according to the method of Olegård and Svennerholm123. 
Gas liquid chromatography (GLC) of methyl esters: The extracts containing the fatty 
acid methyl esters were analyzed in a Perkin Elmer Model 30 apparatus as described in 
paper V. Peaks were quantified by multiplying the height by the width at half height. 
17:0 (heptadecanoic acid, Perkin Elmer) was used as an internal standard. 
Quantification of serum lecithin: Serum lecithin was quantified from the fatty acid con­
tent (obtained by GLC) using a nomogram93. 
Ultracentrifugation (UC) analysis of lipoprotein cholesterol and TG content was perform­
ed on a subsample of 21 patients investigated before the start of treatment (n = 14) and 
during treatment (n = 14). 
Preparative ultracentrifugation of serum was carried out at density (D) 1.006 g/ml and 
1.063 g/ml. 
After lipid extraction, the cholesterol content of supernatant (SUP) and infranatant 
(INF) at D 1.006 g/ml and D 1.063 g/ml and the TG content of SUP and INF D 1.006 
g/ml and SUP D 1.063 g/ml was determined. The average recovery of cholesterol was 97 
per cent (range 72 - 125) at D 1.006 g/ml and 102 per cent (range 69 — 149) at D 
1.063 g/ml. TG recovery at D 1.006 g/ml was 76 per cent (range 55 - 133). 
SUPD 1.006 g/ml was considered to represent the VLDL fraction while INF D 1.063 
g/ml represented HDL. HDL—TG was calculated from serum—TG minus SUP D 1.063 
g/ml. LDL cholesterol and LDL—TG were calculated as (SUP + INF D 1.006 g/ml) minus 
(VLDL + HDL). The relative distribution of cholesterol and TG in the VLDL, LDL and 
HDL was then applied to serum cholesterol and TG values to calculate the absolute 
amount of cholesterol and TG in the different density classes. 
Apolipoprotein composition of lipoproteins: In a subsample of series IV the serum con­
centrations of apolipoprotein A (apo—A), B (apo—B), Cj (apo—Cj), CJJJ (apo—CJJJ) and 
E (apo—E) were determined by electro-immunoassay (EIA) before (n = 26) and after 
three (n = 6) and six months' treatment (n = 12). 
EIA of apo—A was performed as described by Wiklund166 while the EIA of apo—B, — Cj, 
—CJJJ and —E was performed at the Oklahoma Medical Research Foundation, Oklahoma 
City/Oklahoma, USA (Prof. P. Alaupovic) by methods previously described2 . 
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Carbohydrate metabolism: Blood glucose was determined in venous blood by a glucose 
oxidase method (Glox®, AB Kabi, Stockholm, Sweden) and plasma insulin by a solid 
phase antibody technique (Phadebase®, Pharmacia Fine Chemicals, Upsala, Sweden). An 
intravenous glucose tolerance test (IVGTT) was performed as described in paper IV and 
the fractional removal rate (k ) of glucose was calculated as the slope of the log glucose 
values between 20 and 60 min and expressed as per cent disappearance per min. 
Plasma insulin concentration was determined before and at 10, 30 and 90 min after in­
jection of the glucose. Serum lactate concentration was determined in venous blood be­
fore the IVGTT (method Cat No 124.842, Boehringer Mannheim GmbH, FRG). 
Control series 
No control group of non-uremic subjects was investigated in parallel with the uremic pa­
tients. For serum lipids and lipoprotein cholesterol reference groups were found in popu­
lation studies16'78' 88'149'167 carried out at Sahlgrenska sjukhuset using the same 
methods as in the present investigation. Reference values for blood glucose and IVGTT 
in women were also obtained from a population study of 50-year-old women from the 
hospital32, while corresponding values for men were obtained from a population study 
of 50-year-old men, using the same methods, performed in Upsala, Sweden34'83. 
Reference data for the intravenous fat tolerance test were obtained from 31 healthy vol­
unteers with normal serum lipid levels investigated at our laboratory80. The results were 
in close cor respondence with those found by Carlson and Rössner in a similar group47. 
Reference data for UC analyses were obtained from 23 non-renal patients admitted for 
uncomplicated cholecystectomy. 
Results for relative fatty acid composition of lecithin were compared with those of 
matched controls to young men with myocardial infarction166 and healthy women aged 
19 — 34 years137. For LCAT and apo—A, reference values were obtained from the above-
mentioned controls to patients with myocardial infarction and for apo B. apo—Cj, apo— 
CJJJ and apo-E from 50 healthy subjects investigated at the Oklahoma Medical Research 
Foundation2. 
Reference values for lactate were taken from the reference quoted in the kit. 
Reference values for plasma insulin before and during IVGTT were obtained from a study 
of 12 hospitalized patients without renal disease (mean age 67 years) investigated in 
identical fashion at the same hospital108. The basal insulin values of the reference group 
were in close agreement with those obtained in an earlier, larger, healthy control series 
of 49 men and 23 women aged 50 — 55 years30. 
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Methodological considerations 
Laboratory investigations: All patients were investigated before and during treatment, on 
the same day of the week, after 2 — 4 days' hospitalization and the analyses were per­
formed throughout the study by the same personnel at the Metabolic Laboratory. During 
treatment the changes in variables were evaluated at three-months intervals for twelve 
months and also at the last observation during treatment (T), reflecting the total time on 
diet. The mean observation time at T was 9.5 months. 
Typing of hyperlipoproteinemia (HLP) was based on serum lipids, lipoprotein cholesterol 
content and visual inspection of the agarose electrophoresis (paper IV). Marked elevation 
of both cholesterol and TG, a broad ß-band on electrophoresis and an increased ratio of 
VLDL cholesterol to serum TG (> 0.67)62 was suggestive of HLP type III. Regular HLP-
typing was possible to perform in 13 patients (series IV A) while in 15 patients the ratio 
of VLDL cholesterol to serum triglycerides fell well below the expected ratio of 1.0 to 
2.2 (Fig. 3, paper IV), thus preventing the application of the above-mentioned criteria 
for HLP-typing. 
Lipoprotein cholesterol determinations: A correlation (r = 0.87, p < 0.001) was found 
between the different methods of estimating LDL cholesterol, a—Lp cholesterol and 
HDL cholesterol were not correlated, however, and showed a mean difference of 0.45 
mmol/1, HDL cholesterol being higher. This may be explained by the contamination of 
Lp-B in HDL but not in a-Lp166. 
Intravenous fat tolerance test: Reduction of the fractional removal rate (k2) of Intralipid 
can be attributed either to a decreased TG clearance or merely an increased TG pool size. 
Rössner et al.136 have demonstrated the correlation between endogenous TG turnover 
and the fractional elimination rate of Intralipid. However, in several studies the k2 has 
been remarkably unaffected despite considerable changes in TG117'136, raising the ques­
tion of the influence of TG pool size on k2 and competition with TG removal sites. 
Intralipid k2 does undoubtedly reflect chylomicron clearance but the interpretation of 
k2 reflecting endogenous TG clearance may require caution. 
Results before treatment (Paper IV) 
Serum lipids and lipoproteins (Table IV): Serum TG were high in both series, with a con­
comitant increase of phospholipids in the male patients while serum cholesterol was not 
elevated, a—Lp cholesterol was low in both series. VLDL cholesterol was elevated but 
the estimated LDL cholesterol was not. 
UC analyses of lipoprotein composition (Fig. 14) revealed that both the content and re­
lative distribution of cholesterol was increased in VLDL, decreased in HDL and un­
changed in LDL. TG was markedly increased in V LDL, as expected, but not in LDL or 
HDL. 
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Series A Series B Control series 
Serum cholesterol 5.9 ± 0.3 6.0 + 0.3 men: 6.2 ± 0.11 
(mmol/1) women: 7.1 ± 0.05 
Serum triglycerides 3.2 ± 0.4+++ 3.2 ± 0.3+++ men: 1.3 ± 0.09 
(mmol/1) women: 1.3 ± 0.03 
Serum phospholipids 3.0 ± 0.1+ 2.9 + 0.1 men: 2.7 ± 0.06 
(mmol/1) women: 3.0 ±0.11 
Lipoprotein cholesterol 
(mmol/1) 
VLDL 1.3 ± 0.3+++ 1.2 ± 0.2 +++ men: 0.5 ± 0.04 
women: 0.3 ± 0.02 
LDL 3.4 ± 0.3 3.6 ± 0.2 
a —Lp 1.2 ± 0.1 ++ 1.2 + 0.1++ men: 1.5 ± 0.03 
women : 1.7 ± 0.04 
FFA 519 ± 38 544 ± 43 918 ± 115 
(Mmol/1) 
IVFTT-k2 4.2 ± 0.74" 4.3 ± 0.5 + men: 6.0 ± 0.4 
(%/min) (n = 10) (n = 13) women: 6.8 ± 0.6 
Table IV. Serum lipids (cholesterol, triglycerides, phospholipids), lipoprotein cholesterol 
(VLDL, LDL, a-LpJ, non-esterified fatty acids (FFA) and intravenous fat tolerance test 
in uremia. Mean (± SEJ for men (series A, n = 20) and total series (series B, n =28) in re­
lation to appropriate control series (paper IV).+ = p <0.05,++ = p <0.01,+++ = p < 
0.001. 
Typing of hyperlipoproteinemia (HLP) was possible to perform in 13 out of 28 patients 
(cf. Methodological considerations). Five men and one woman had a normal lipoprotein 
pattern, one patient had type Ha, one patient type III and five patients had type IV HLP. 
Intravenous fat tolerance test (Intralipid) (Table IV; fig. 5, paper IV) showed a reduced 
fractional removal rate (k2) of Intralipid but the relationship between k2 and TG was 
of the same magnitude in our series as in the normo- and hyperlipidemic non-renal con­
trol series. 
Fatty acid composition of lecithin (Fig. 15): In the male uremic patients (n = 20) the fat­
ty acid composition of lecithin was not different from that in control men except for a 
lower (p =< 0.001) content of arachidonic (20:4) acid, while stearic (18:0) acid was in­
creased (p < 0.01). In females (n = 8) there was an increase in palmitic (16:0) (p < 0.05) 
and oleic (18:1) (p < 0.01) acids while linoleic (18:2) and arachidonic (20:4) acids were 
lower (p < 0.05) compared to the non-uremic controls. 
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TRIGLYCERIDES 
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before treatment (n=14) 
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Fig. 14. Mean (± SE) cholesterol and triglyceride content of VLDL, LDL, HDL, deter­
mined by ultracentrifugation, and totalserum in uremic patients (series IV) before (n = 
14) and during treatment (n = 14) and in co ntrol series (n= 23). Differences between pa­
tient series and control series are indicated:* = p < 0.05,++ =p < 0.01,*++ = p < 0.001. 
LCAT (Fig, 16): The mean LCAT activity was 87.3 ± 25.1 (SD) imîol CE/l/h (n = 17), 
compared to 98.7 ± 24.9 in the control group (n = 40). These results would indicate low­
er LCAT in uremia, taking into account the higher mean triglyceride levels in th e uremic 
patients, although the difference is not statistically significant (p < 0.10). 
Apolipoproteins (Fig. 17): Apo—A, apo—B and apo—E levels were low while apo—Cj 
and especially apo—C[jj were high compared to the controls. 
Carbohydrate metabolism (Table V; fig. 2, paper IV): Mean fasting blood glucose levels 
were slightly elevated in the female patients, compared to the control series while the re­
verse was the case in the male series. The IVGTT revealed a low (p < 0.01) estimated k-
value in both series. 
Mean basal plasma insulin was no t elevated nor were mean insulin levels during the 
IVGTT but serum lactate was low in both series. However, the increase in plasma insulin 
at 10 min was fourfold in the patient series, compared to a 2.7 fold increase in controls. 
Correlations among lipid and carbohydrate variables: 
Serum TG was well correlated to VLDL-TG (r = 0.85, p < 0.001, n = 14) and to VLDL 
cholesterol (r = 0.71, p < 0.001, n = 33) and also inversely correlated to a—Lp cholesterol 
(r = —0.57, p < 0.001, n = 33) but not to HDL cholesterol. 
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Fig. 15. Relative major fatty acid composition of lecithin in patients with uremia (n = 
28) in per cent ( mean ± SD) of means, of control series. The relative contents of palmitic 
(16:0), oleic ( 18:1), linoleic ( 18:2) and arachidonic (20:4) acids in men and women are 
shown. 
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Fig. 16. LCAT activity in 17patients with 
uremia before dietary treatment. The 
frame indicates mean ± SD of control 
series. 
0 month 
Serum TG was also correlated to basal plasma insulin (r = 0.44, p < 0.05, n = 28) and in­
sulin during IVGTT (r = 0.56, p < 0.05, n = 26) (Fig. 4, paper IV) but not to BW or 
BW/SW. 
Serum cholesterol was correlated both to VLDL (r = 0.45, p < 0.01, n = 33) and to LDL 
cholesterol (r = 0.80, p < 0.001, n = 33). In LDL, the cholesterol content was correlated 
to the TG content (r = 0.76, p < 0.01, n = 14). 
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Fig. 17. Serum concentration of 
apolipoprotein A (Apo-A), B 
(Apo-B), Cj(Apo-Cj), 
C m (Apo-Cin) and E (Apo-E) 
in patients with uremia before 
dietary treatment. 
Broken lines: mean values, 
frames: mean ± SD of control series. 
Apo-A Apo-B Apo-Cj Apo-C^ Apo-E 
Series A Series B Control series 
Blood glucose 
(mmol/1) 
IVGTT-k 
Plasma insulin 
(mU/1) 
0' 
10' 
£ insulin 
Serum lactate 
(mmol/1) 
4.5 ± 0.1+  
0.92 ± 0.06++ 
12.6 ± 1.5 
47 ± 5.7 
128 ±11 
0.6 ± 0.05++ 
4.6±0.1+  
0.92 ± 0.07++ 
13.5 ± 1.3 
50 ± 4.7 
129 ± 10 
0.7 ± 0.04 ++ 
men: 4.9 ±0.06 
women: 3.9 ±0.02 
men: 1.62 ± 0.07 
women: 1.88 ± 0.06 
15 ± 3 
37 ± 5 
113 ± 12 
1.4 ± 0.04 
Table V. Blood glucose, intravenous glucose tolerance test (IVGTT), plasma insulin 
during IVGTT and serum lactate in uremia. Mean (±SE) for men (series A, n = 20) and 
total series (series B, n = 28) in relation to appropriate control series (paperIV). + =p 
<0.05,++ =p <0.01. 
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Fig. 18. Serum concentration of apolipo-
protein Cjjj(Apo-Cjjj) versus (log) 
serum triglycerides (TG) in patients with 
uremia before dietary treatment (r= 0.61, 
p < 0.01, n =22). 
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Plasma insulin was correlated to BW/SW (r = 0.67, p < 0.001, n = 28) but also to fasting 
blood glucose (r = 0.43, p < 0.05, n = 28). 
Intralipid k2 was inversely correlated to serum TG (Fig. 5, paper IV). There was also a 
tendency towards a negative correlation (r = -0.55, p = 0.05, n = 13) between k2 and 
serum urea. 
There was no correlation between lecithin relative fatty acid composition and the various 
lipid variables. 
LCAT showed a weak correlation to serum TG (r = 0.46, p = 0.05 < p < 0.10, n = 17) 
and none to apo—A or a—Lp cholesterol. 
Apolipoproteins: Apo—A was (as might be expected) correlated to a—Lp cholesterol (r = 
0.65, p < 0.05, n = 14) but not to any other apolipoproteins. 
Apo—B was closely correlated to serum cholesterol (r = 0.51, p < 0.01, n = 26) but also 
to apo—E (r = 0.69, p < 0.01, n = 16). Apo—CJJJ showed a co rrelation (r = 0.61, p < 
0.01, n = 22) to serum TG (Fig. 18). 
GFR was not correlated to lipid or carbohydrate variables. 
Results during dietary treatment, mean 9.5 months (Table III, paper V) 
GFR decreased continuously (Fig. 19) while serum urea decreased initially, after which 
there was a slow rise. 
Mean serum albumin was low (but within the normal range) before the start of treatment 
and remained so during treatment. 
The mean serum transferrin (TIBC) levels underwent on average a 12 per cent decrease 
during treatment (p < 0.05). However, transferrin remained within the reference limits 
(43 — 90 jumol/1) even at time T. 
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Fig. 19. Glomerular filtration rate (GFR, solid line), serum urea (S—UREA, broken line), 
serum cholesterol (open bars) and serum triglycerides (striped bars) during die tary treat­
ment of uremia. Mean ± SE before (0 month) and at 3, 6, 9 and 12 months and at last 
observation (T) during treatment (n = number of patients). 
Serum lipids and lipoproteins: There was no change in mean serum TG, cholesterol, phos­
pholipids, lipoprotein cholesterol or FFA during treatment (Fig. 19). TG increased at 
time T by > 25 per cent in 1 out of 22 patients but there was an equally large decrease 
in 3 patients. UC analyses of TG and cholesterol in VLDL, LDL and HDL did not dis­
close any change from start of treatment to time T (n = 6). 
Fatty acid composition of lecithin: Lin oleic (18:2) acid and the sum of (n —6) acids in­
creased during treatment, with a maximum at 6 months (p < 0.05), with inverse changes 
in pa lmitic (16:0) acid. Plasma lecithin was also increased (p < 0.05) at 6 months. 
Mean LCAT activity and mean apolipoprotein values did not change during treatment. 
Carbohydrate metabolism (Table VI): Mean fasting blood glucose levels remained un­
changed as did mean IVGTT-k. Mean plasma insulin values were also unchanged. Serum 
lactate was low before dietary treatment and remained so during treatment. 
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0 month 6 months 12 months T 
X ± SD XA n XA n XA n 
Blood glucose 
(mmol/1) 
4.6 0.5 -0.3 16 — 0.6 10 -0.2 18 
IVGTT-k 
(%/min) 
0.99 0.34 -0.03 16 -0.12 9 -0.06 13 
Plasma insulin 
(mU/1) 
0' 13.7 6.1 -1.7 16 -1.3 9 -2.4 13 
10' 52.5 25.2 -3.5 15 -2.2 9 
00 oo I 13 
S insulin 132.4 48.3 -12.7 15 + 3.4 9 -15.2 13 
Serum lactate 0.7 0.2 -0.2 15 + 0.4+ 9 + 0.3 12 
(mmol/1) 
Table VI. Blood glucose, intravenous glucose tolerance test (IVGTT), plasma insulin 
during IVGTT and serum lactate during dietary treatment of uremia. Mean (±SD) 
before treatment (0 month) in total series (n=22) and mean difference (X^Jfrom 0 
month at 6 and 12 months and at last observation during treatment (T). * = p <0.05, 
n = number of patients. 
Correlations among changes in lipid and carbohydrate variables 
The observed changes (A) in TG, cholesterol or a—Lp cholesterol were not correlated to 
changes in GFR or urea, to time on diet or to changes in BW. There were no correlations 
between A-TG and composition of diet (energy, fat, carbohydrate or sucrose content or 
P/S-ratio), However, the changes in serum cholesterol (A—cholesterol) were negatively 
correlated to the total amount of fat in the diet (r = —0.51, p < 0.05) and to the P/S-
ratio (r = —0.54, p < 0.05) (Fig. 20). The changes in a—Lp cholesterol also tended to be 
correlated to the amount of fat in the diet (r = 0.41, p = 0.11, n = 16). 
Fatty acid composition of lecithin: The changes in relative content of palmitic (16:0) acid 
tended to be negatively correlated to the P/S-ratio in the diet (r = -0.60, p = 0.05) and 
to time on diet (r- —0.53, p = 0.05). The relative content of linoleic (18:2) acid, on the 
other hand, increased with increasing P/S-ratio (Fig. 20). 
Changes in 18:2 acid were negatively correlated to changes in 16:0 acid (r = -0.76, p < 
0.01, n = 14) and to changes in 20:4 acid (r = —0.63, p < 0.05, n = 14). Changes in serum 
TG were not correlated to changes of relative fatty acid composition of lecithin. 
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Apolipoproteins: The changes in apo—B were correlated to those in apo—Cj (r = 0.75, 
p < 0.01, n = 11), in apo—Cjjj (r = 0.61, p < 0.05, n = 12) and in apo—E (r = 0.72, p < 
0.05, n = 8) but also to the change in serum cholesterol (r = 0.82, p < 0.001, n = 13). 
Changes in apo—Cjjj were also correlated to those in serum TG (r = 0.59, p < 0.05, 
n = 12). 
Changes in apolipoprotein content were not correlated to those of other serum proteins 
e.g. albumin or TIBC, or to diet composition. 
CHOL 
A 18:2 mol <%> 
I0. 
30 60 90 PF 
Fig. 20. Changes in serum cholesterol ( ACM OL j and in relative content of linoleic ( 18:2) 
acid ( A 18:2) versus content of polyunsaturated fat (PF) in diet (P/S x dietary fat in 
grams) during dietary treatment of uremia. Changes in serum cholesterol are expressed as 
the logarithmically transformed ratio cholesterol at last observation (T)/cholesterol be­
fore treatment while changes in linoleic acid are expressed in mole per cent. (A.CHOL vs 
PF:r = -0.59, p<0.05, n = l 7; M8:2 vs PF: r = 0.77,p< 0.05, n = 10). 
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DISCUSSION 
Indications and contraindications for dietary treatment 
The aim of the dietary treatment should be relief of uremic symptoms and maintenance 
of a good nutritional state without further deterioration of the disturbances in lipid and 
carbohydrate metabolism, preparing the patient for future treatment with dialysis or 
transplantation or in some cases to achieve good palliation. The treatment is, in a broad 
sense purely symptomatic and inflicts a definite strain on the daily life of the patient. 
Patient motivation is therefore the key to successful treatment and is created by amelior­
ation of symptoms and increased wellbeing. Thus, only patients with symptoms of renal 
failure are suited for treatment. Patients with terminal uremia complicated by serositis, 
oliguria or severe neuropathy, on the other hand, do not benefit from dietary treatment. 
The rate ofGFR decrease is the most important single factor determining the duration 
of successful conservative management. Patients with uremic manifestations of similar 
degree show great differences in serum creatinine levels (paper I). The observed inaccu­
racy of serum creatinine and endogenous creatinine clearance for estimation of GFR 
(paper I) might be due to several factors, above all variations in tubular excretion of crea­
tinine86, fluctuations in creatinine production over the day and between days126 and the 
methodological errors in the serum creatinine determinations. slCr-EDTA was an equal­
ly good filtration marker as inulin, which was used as reference substance for the deter­
mination of GFR86 , but analysis of inulin is more cumbersome for clinical purposes. The 
plasma clearance of51 Cr—EDTA (Fig. 8), the so-called slope clearance, (calculated from 
the plasma disappearance curve of the marker) did not provide an accurate measure at 
low GFR owing to the variable extrarenal clearance of the marker, as also found with 
normal or moderately reduced GPR^ 42. In addition, the slope of the disappearance curve 
was so small that determination of the area under the curve was difficult to perform with 
a reasonable degree of precision. Accurate determination of GFR in advanced renal in­
sufficiency thus required an external filtration marker (inulin or51 Cr-EDTA), with urine 
collection, and was routinely applied in t he later patient series (IV). 
Our data indicate that the therapeutic interval for dietary treatment seems to be from on­
set of uremic symptoms (GFR between 6.5 and 9.5 ml/min) until a GFR of about 4 ml/ 
min (Fig. 9). Similar studies with accurate determination of GFR have not been publish­
ed to our knowledge. Walser161 has estimated the GFR limit to be about 3 per cent of 
normal. Pre-treatment determinations of GFR thus appear to be of practical value. It was 
also apparent (Fig. 9) that the rate of GFR decrease tended to be fairly uniform in the 
present series irrespective of the original disease. 
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Choice of diet 
The dietary treatment of uremia in Gothenburg has been based on direct introduction of 
the 20 g protein diet when uremic symptoms appear. In a small group of patients with 
stable or unusually slowly progressing functional impairment treatment with a 40 g pro­
tein diet could be used. In most patients with progressive renal failure, however, the thera­
peutic period for the 40 g diet will be short. The patients would then have to learn two 
rather different diets within a short period of time. 
Supplementation of the diet with essential amino-acids and histidine (EAAH) 
The supplementation improved nitrogen balance in all patients. It is doubtful whether 
the difference in apparent nitrogen balance (0.57 g N/24 h) between 2.6 N i.v. and 1.3 g 
N by mouth has any biological significance. Furthermore, the corrected apparent nitro­
gen balance tended to be better with 1.3 g N by mouth than with 2.6 g N i.v. With 1.3 g 
N as EAAH, oral administration tended to be superior to infusion. 
There is no readily available explanation for the finding in series II that the utilization of 
EAAH for protein synthesis was better when it was given orally than by the parenteral 
route. Similar conclusions have been made from studies in non-uremic individuals156. 
Intravenous infusion of amino-acids, particularly if done rapidly, may lead to immediate 
excretion in the urine or direct catabolism of the amino-acids. The hyperglucagonaemia 
of renal failure29 might prevent full utilization of the infused amino-acids for protein 
synthesis. Oral amino-acids might also elicit a different insulin response than i.v. amino-
acids154 , contributing to better amino-acid utilization. However, 2.6 g N as EAAH admin­
istered i.v. or by mouth in u remia has been found to give the same nitrogen balance but 
with a different amino-acid incorporation pattern in body proteins22 . 
The effect of 2.6 g N by mouth was not investigated. It has, however, been shown by 
Bergström et al.23 that a similar 20 g diet supplemented with 2.6 g N as EAAH by mouth 
gave an uncorrected mean nitrogen balance of +0.57 g N/24 h in close agreement with 
our results with only half that amount. 
Our data would seem to indicate that routine supplementation with 1.3 g N orally as 
EAAH should be adequate for the stable adult uremic patient and that increase of EAAH 
above this level does not improve the nitrogen balance further to any great extent. It is 
of practical advantage for the patient to keep the EAAH supplementation at a lower level 
provided no deterioration of the nitrogen balance occurs. Together with the amino-acids 
in the diet, the calculated daily intake of essential amino-acids amounts to twice the 
minimum requirement134 or more (Fig. 6). 
It has been suggested that the composition of the amino-acid supplementation may be 
suboptimal since in uremia low intracellular concentrations of tryptophan, valine and ty-
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rosine have been found together with an elevated phenylalanine/tyrosine ratio24'150. The 
amino-acid mixtures could, on theoretical grounds, be altered accordingly, with addition 
of tyrosine and increase of the tryptophan and methionine content, being low in the 
supplemented diet. 
Adherence to diet 
Previously reported data on dietary adherence in uremic patients have been obtained dur­
ing hospital conditions or in the metabolic ward and are not directly comparable with 
those obtained in the present study during routine outpatient treatment over a longer 
period of t ime. 
Our data indicate that the adherence to the prescribed diet was good (Table II) even when 
checked on repeated occasions, with less than 15 per cent mean variation of energy and 
protein intake. Although the fat and sucrose contents were well above recommended 
levels for healthy subjects the diet was sufficiently varied and palatable to be to lerable 
for the patients. Furthermore the large amounts of fat and sucrose gave cause for inves­
tigation of the influence of the diet on lipid and carbohydrate metabolism. 
During the study we have gained the experience, that adherence to diet depends on the 
skill of the dietitian in adapting the diet, as far as possible, to the ordinary food habits of 
the patient and his family. Together with the culinary demands, these circumstances ex­
clude the use of special formula diets etc. 
Long-term aspects of protein metabolism during dietary treatment of 
uremia 
The average patient with chronic renal failure and early uremic symptoms had a relative­
ly maintained body composition also during dietary treatment unless the situation was 
complicated by catabolic stress, intercurrent illness or major nutritional difficulties. 
The nitrogen balance data indicated that a low-protein diet supplemented with EAAH 
improved the nitrogen balance but that several patients were still in a slightly negative 
balance when all losses were taken into account. These data, together with body compo­
sition data, therefore indicate that in many cases a fu rther adaptation to reduced nitro­
gen intake must have taken place over a longer period of time in accordance with the 
findings in non-uremic patients147. 
A slight decrease of BCM without increase of TBW, however, was found in a few male 
patients despite very good clinical results and maintained BW over 12 months. They all 
had markedly low serum urea levels during treatment and it is conceivable that the 
amount of endogenous nitrogen was insufficient and their total nitrogen intake conse­
quently slightly too low. Apart from the finding of decreasing TBK values these patients 
were not clinically distinguishable from the patients with the most promising clinical re­
sults. 
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Data on body composition validated the assumption that long-term dietary treatment 
with the EAAH supplementation used in this study is sufficient to prevent a clinically 
important protein malnutrition, unless the further course (until terminal uremia) is com­
plicated by intercurrent disease. Our clinical results with this long-term treatment were 
in accordance with those in a comparable series of patients with chronic renal failure, 
treated with a similar diet, but with a larger amino-acid supplementation121. No clinical 
evidence of malnutrition, serum protein depletion or progress of neuropathy was found 
in that series either. 
Serial determinations of body composition during treatment with EAAH-supplemented 
diet have to our knowledge not been reported before, but in a number of series of pa­
tients treated for varying periods of time with a protein-reduced diet BCM has been found 
to be maintained26'31'3S' 60'103'115. 
Since mean BW, BCM, and TBW remained unchanged, this also applies to body fat, there­
by indicating that the energy stores were generally maintained and that sufficient energy 
was supplied by the diet. The lack of correlation between changes in BW and TBK or 
TBW, might also indicate that in renal failure, changes in BW do not necessarily reflect 
the nutritional state. 
Data on serum albumin and transferrin support the interpretation of maintained nutri­
tional status and the slight decrease (12%) of transferrin could have been influenced by 
the iron supplementation and also a systematic trend towards lower values over the years 
covered by the investigation. 
Lipid and carbohydrate metabolism in chronic renal failure 
Carbohydrate metabolism 
In the present series of uremic patients, the glucose utilization rate was reduced, with a 
low k-value at IVGTT (< 1.1 in 23 out of 28 patients), while blood glucose levels were 
within normal limits, as was plasma insulin, both in the fasting state and after a glucose 
load. This would indicate a resistance to the glucose assimilation by insulin in uremia as 
has earlier been demonstrated in man52'S3'165 as well as in experimental uremia in the 
dog151. 
Furthermore, the metabolic clearance of insulin is delayed in renal failure, with increase 
of both plasma insulin, proinsulin and C-peptide52'53'92' n1'130. In the present study, 
lack of hyperinsulinaemia (in spite of prolonged elevation of blood glucose during a glu­
cose load) might therefore be related to a defect in insulin release from the uremic pan-
52 130 créas ' . 
In the context of the suggested insulin resistance the recent finding by Lutz109 of an in­
sulin "insensitivity" owing to formation of a complex between insulin and a basic poly-
amine-containing polypeptide accumulating in u remia, is of great interest. It should be 
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pointed out, however, that in the present series no correlation was found between serum 
urea or GFR and plasma insulin or the k-value in the IVGTT. 
The unexpected finding in t his series of low lactate levels may also be related to this sug­
gested insulin resistance, causing higher utilization of lactate in gluconeogenesis. 
Lipid and lipoprotein metabolism 
Increased serum triglycerides (TG) (hypertriglyceridemia) as found in the present study 
(paper IV, V), has been a regular finding in uremia10' n'51 ' 90 ' 120. In the present study 
serum phospholipids were also elevated simultaneously with the increase in TG while 
serum cholesterol was within the "normal" range. The cause of the hypertriglyceridemia 
was chiefly an increase in very-low-density lipoproteins (VLDL), but the VLDL choleste­
rol was not always increased in proportion to serum TG, thereby indicating that lipopro­
teins of higher density, i.e. low-density lipoproteins (LDL) and high-density lipoproteins 
(HDL), could be enriched in TG. This was not verified in the lipid analyses on ultracentri-
fugal fractions (UC), however. However the cholesterol content in HDL, as well as in a~ 
Lp, was lower than in control series, and also lower than might be expected in rela tion to 
the hypertriglyceridemia78. That is, the HDL composition was characterized by an in­
creased TG to cholesterol ratio (fig. 14). In agreement with these findings, the apolipo-
protein content, apo—A, was also low (fig. 17). Low HDL cholesterol9'90'120 as well as 
low a—Lp105 has been found in uremia, while, in an earlier study, where apo—A was 
measured in whole serum39, this protein moiety appeared to be normal in uremic patients 
on dialysis. 
Hypertriglyceridemia (in the post-absorbtive state) is due either to an increased produc­
tion or to a decreased clearance of TG-rich lipoproteins, VLDL or chylomicrons, or to a 
combination of both these mechanisms. 
An increased production of VLDL (from the liver) could be enhanced by increased avail­
ability of TG substrates i.e. fatty acids as FFA, liberated by lipolysis from adipose tissue, 
and of glycerol from glucose via «-glycerophosphate (cf. Introduction). 
In the present study the level of FFA was initially, if anything, low, which is surprising 
in view of the fact that these patients could be expected to be in a catabolic state. 
Furthermore, increased levels of circulating catecholamines and cAMP, as found in 
uremia81'142 would be expected to enhance adipose tissue lipolysis. However, a normal 
or even a low level of FFA could still be compatible with an increased turnover of FFA, 
and with substrate excess for TG synthesis. An increased glycerol release from adipose 
tissue indicating enhanced lipolysis has been found in uremia157. A high utilization of 
FFA for TG synthesis in the liver could be further promoted by a lower fatty acid incor­
poration in adipose tissue (FIAT) in the uremic patients157. 
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In relation to TG substrate, blood-glucose levels were not elevated in most patients, and 
neither was fasting plasma insulin, as judged from mean values (paper IV). However, there 
was a relationship between plasma insulin and serum TG, which has often been interpret­
ed as indicating an influence by insulin on TG synthesis and VLDL secretion11'124. 
TG production and VLDL secretion from the liver has also been suggested to be enhanced 
by certain fatty acids95. In our female patients the relative fatty acid composition of 
plasma lecithin indicated a small increase of palmitic (16:0) acid and decrease of linoleic 
(18:2) acid, but it is doubtful whether these mariginal changes could influence on liver 
TG synthesis and were furthermore corrected during dietary treatment. 
In connection with the recently launched lipoprotein family concept, it has been suggest­
ed2 that the relative distribution of lipoprotein families in se rum might also be used as a 
guidance to the genesis of hypertriglyceridemia. Thus, an increased relative content of 
polypeptide CJJJ has been taken as an expression of increased hepatic TG synthesis and 
VLDL secretion2. There was a strikingly high level of Cm in our uremic patients (Fig. 
17), and furthermore a correlation between se mm TG and the CJJJ levels (Fig. 18). 
The alternative cause of hypertriglyceridemia is a decreased clearance of VLDL and chylo­
microns. The TG distribution among lipoprotein fractions would favour this mechanism 
as a major cause of hypertriglyceridemia in our series of uremic patients. The appearance 
of a typical HLP type-Ill pattern in one patient as well as of a type-Ill index155 > 1.2 in 
7 out of 14 uremic patients in the present series would indicate the presence of inter­
mediate low density lipoproteins ( I LDL) (cf. introduction) and thus would most likely 
be an express ion of a reduced catabolic rate of VLDL to LDL. This would be in agree­
ment with earlier findings in uremia10'90'120. Furthermore, in the present study the TG 
clearance rate, studied as fractional removal of TG as Intralipid particles, was reduced. If 
it can be assumed135'136 that the fractional turnover of Intralipid particles is an expression 
of the turnover of VLDL, this finding would imply further evidence for a reduced cata­
bolic rate of VLDL in uremia. 
In uremia lipoprotein lipase (LPL) activity is generally reduced, both in post-heparin 
plasma11'51'113'116 and in adipose tissue40'129, even though the enzyme content per se 
may be unchanged13. Preliminary data on a subsample of the present patient series would 
indicate, in accordance with recently published data on LPL activity in uremia113, that a 
reduction of the hepatic triglyceride lipase (HTG) accounts for a major part of the de­
crease of the post-heparin lipolytic activity in plasma. This deficiency could contribute 
to the appearance of ILDL and hypertriglyceridemia. 
Furthermore, analysis of lecithin xholesterol acyl transferase (LCAT) activity may be of 
value in the evaluation of the mechanism for hypertriglyceridemia158. Our data indicate 
a reduced LCAT activity in relation to serum TG, which again would be expected to be 
related to a reduced conversion of VLDL to LDL72 (cf. introduction). On the other 
hand, a reduced LCAT might also be secondary to a general impairment of liver protein 
synthesis in uremia33 (cf. intermediary metabolism). 
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In the context of the lipoprotein family concept and in the light of recent findings2' 67, 
and also in view of our findings of strong indication of a reduced catabolic rate of VLDL 
the low content of apo—E is surprising. One characteristic finding in non-uremic hyper-
triglyceridemic patients with marked increase in serum TG (> 5.0 mmol/1) is a simul­
taneous marked increase of apo—E as also found in type III hyperlipoproteinemia67. 
Again, however, in the catabolic state of the uremic patient, a depression of apo—E syn­
thesis59 could still be a possible explanation for the lack of a characteristic apo—E in­
crease (cf. intermediary metabolism). In this context, it should be remembered that also 
the liver-synthesized apolipoprotein B tended to be low, possibly also as an expression 
of a reduced protein synthesis. 
These studies in uremic patients indicate a reduced catabolic rate of VLDL—TG as the 
main cause of hypertriglyceridemia, and this would agree with recent experience from 
TG turnover studies, demonstrating a low catabolic rate of TG-carrying lipoproteins in 
uremia in man48 and in the rat13'75. It should be emphasized, however, that in uremia 
the validity of the present approach to TG turnover studies may still be questioned119. 
Furthermore, our studies with dietary management as a means of correcting the meta­
bolic situation in uremic patients showed that a protein-reduced diet with increased carbo­
hydrates (as sucrose), and fat did not unfavourably influence the serum TG level and 
thereby serum TG formation in the liver, as would have been expected if an increased TG 
synthesis had been a basic metabolic defect in uremia. 
Influence by drug treatment on lipid and carbohydrate metabolism 
Although the number of patients not on beta-blocking agents (alprenolol, propranolol) 
was low (n = 5) in the present series (IV), the difference in serum TG values could be of 
interest. In the 23 patients treated for hypertension with beta-blocking agents the mean 
serum TG value was slightly higher (3.4 vs 2.5) than in the five u ntreated patients. This 
finding is interesting in view of similar findings recently obtained in uremic patients on 
dialysis39, where beta-blockade was linked to a higher serum TG value. Therefore, the 
possibility that the use of be ta-blocking agents in uremia contributes to derangements in 
lipid metabolism, cannot be ruled out. 
Influence of dietary treatment on lipid and carbohydrate metabolism 
The reduction in clinical manifestations of uremia during dietary treatment was possibly 
due to beneficial influences on certain fundamental factors also contributing to the ab­
normalities in lipid and carbohydrate metabolism63'141. This general beneficial influence 
of the diet might partly be related to the avoidance of excessive energy supply by the 
diet141 but may also be due to an increased physical activity and energy expenditure. On 
the other hand, if an energy deficiency had been present as an explanation for maintain­
ed lipid levels during treatment, the constancy in body composition would not have been 
expected. 
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Furthermore, the dietary treatment did not influence the glucose utilization rate or 
plasma insulin values, as has been observed after dialysis50's2'S3'153 in spite of a sub­
stantial decrease in serum urea. Interestingly enough, the earlier verified relationship be­
tween plasma insulin and serum TG was lost during dietary treatment. 
Serum lipids and serum lipoproteins, as well as variables relating to glucose metabolism, 
did not change during dietary treatment, although the sucrose intake was high. Individual 
TG changes (including 7 out of 22 patients with a marked increase) were not correlated 
to either carbohydrate or total fat and total energy intake or the content of polyunsatu­
rated fat in the diet. This lack of influence of the high sucrose content in the d ; t should 
be compared with corresponding results in short-term studies in non-uremic patients45, 
where the serum TG was increased concomitant with a reduced elimination rate of exo­
genous fat (Intralipid) and a reduction in the relative content of plasma lecithin linoleic 
(18:2) acid. 
The high fat content in t he protein-reduced diet did not appear to have an unfavourable 
effect on serum lipids or lipoproteins, which was possibly related to the relatively high 
content of polyunsaturated fatty acids in the diet. In short term studies in uremia, a 
marked increase of polyunsaturated fat (concomitant with a reduction in carbohydrates) 
has been shown to decrease TG production and serum TG values138. This favourable ef­
fect on serum TG of polyunsaturated fat in the diet may in addition be related to an in­
creased TG elimination rate117. 
In contrast to the lack of influence on serum TG, serum cholesterol changes were related 
to dietary fat intake in the diet, with a decrease in relation to a higher polyunsaturated 
fat intake, in accordance with findings in non-uremic subjects. An additional interesting 
finding was that the «-lipoprotein cholesterol changes appeared to parallel those of serum 
cholesterol in relation to total fat and polyunsaturated fat intake. 
Finally, the apolipoprotein content in serum was not to any great extent influenced by 
the protein-reduced diet, possibly indicating that low pre treatment values of apo-B, D 
and E were not related to an inadequate intake of protein or essential amino-acids (cf. 
Intermediary metabolism). 
Lipid and carbohydrate metabolism and atherosclerosis in uremia 
Certain of the abnormalities of lipid and carbohydrate metabolism found in the present 
study, could be associated with the development of atherosclerosis in uremia. 
Lipoprotein content and composition: Increased VLDL content of cholesterol and tri­
glyceride as well as abnormal HDL composition with increased relative content of trigly­
ceride and reduced content of apolipoprotein A were characteristic findings in male pa­
tients with myocardial infarction166 and those were also our findings in uremia. 
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An isolated increase of apolipoprotein CJJJ together with elevated triglyceride levels was 
a second characteristic of the lipoprotein pattern in uremia but the possible association 
with atherosclerotic vascular disease needs further study. 
Insulin resistance with normal or elevated plasma insulin levels are additional apparent 
features in patients with myocardial infarction164 particularly in connection with hyper­
triglyceridemia and moderate obesity. Moreover a correlation has been demonstrated be­
tween plasma insulin and the cholesterol content of the arterial wall363. Insulin resistance 
appears to be an important characteristic of uremia, although the plasma insulin levels 
were not elevated in the present study, and could be of importance for development of 
atherosclerosis. 
The dietary treatment did not influence on the above mentioned abnormalities and 
should in this respect not excert a further negative influence on the development of vas­
cular disease. However, it appears to be of considerable interest to further investigate 
these abnormalities of lipid and carbohydrate metabolism in uremia and also in connec­
tion with the rapid improvement in renal function after a successful renal transplantation. 
Intermediary metabolism in uremia and the influence of dietary treatment 
In uremia derangements of pro tein as well as of lipid and carbohydrate metabolism occur 
and the similarities to the metabolic situation in malnutrition have often been pointed 
out61. 
Although the genesis to these derangements is multifactorial, one important basic abnor­
mality appears to be a disturbance in insulin action. This is characterized by an insulin 
resistance together with a relatively decreased pancreatic insulin response to hyperglyce­
mia (Fig. 21). 
The insulin resistance has been related to several factors like: 
— accumulation of inhibitory metabolites109, 
— increased levels of insulin antagonists e.g. catecholamines142, glucagon29 and growth 
hormone (particularly when uremia is accompanied by malnutrition)12' 50'S2'87, 
— potassium depletion or disturbances of calcium homeostasis due to secondary hyper-
parathyreoidism3' 28'52 and 
— adaptation to transient hyperinsulinemia, due to decreased metabolic clearance of in­
sulin, during the earlier course of renal insufficiency52'61'130. 
In uremia there is thus a combination of insulin resistance and a normal or only slightly 
elevated plasma insulin while fasting blood glucose is usually not elevated. This metabolic 
situation differs from that in adult onset diabetes and in hypertriglyceridemia associated 
with obesity, where insulin resistance is usually accompanied by elevated plasma insulin 
levels102'124. This relative insulin deficiency in uremia may be expected to be accompa-
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nied by several basic defects in the intermediary metabolism and also associated with the 
dietary treatment (Fig. 22). 
A decreased peripheral glucose utilization primarily affecting muscle tissue. This defect 
may be partially overcome by increased physical activity concomitant with relief of ure­
mic symptoms during dietary treatment (cf. Introduction). 
An increased formation of glucose65 from lactate, amino-acids and glycerol (Fig. 22). The 
low plasma lactate levels found in the present series could be an expression for a com­
pensatory overutilization of lactate in gluconeogenesis (cf. Introduction, Intermediary 
metabolism). On the other hand a low protein intake could limit the utilization of amino-
acids in gluconeogenesis. 
A decreased amino-acid utilization in protein synthesis. This decrease of protein syn­
thesis could affect not only structural proteins (like cellular proteins in e.g. muscle tissue) 
and transport proteins (apolipoproteins, serum proteins) but also synthesis of specific en­
zymes e.g. LCAT33'77 (cf. Lipid metabolism). Decreased synthesis of protein in the liver 
may be reflected by the low plasma albumin and in the present study, also a low content 
of specific apolipoproteins. Apo—B and apo—E (presumably formed in the liver) were 
unexpectedly low in relation to other metabolic findings (cf. Lipid metabolism). Low 
plasma LCAT activity (cf. Lipid metabolism) might possibly also be an expression of a 
low level of protein synthesis (and enzyme availability) in relation to uremic insulin de­
ficiency. LCAT is known to be a sensitive p rotein enzyme, easily influenced by liver dis­
ease and disturbances of protein synthesis33. Other enzymes of considerable interest in 
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relation to hypertriglyceridemia are the lipoprotein lipases, particularly the hepatic TG 
lipase (HTG) (cf. Lipid metabolism) which has been found to be r educed in uremia and 
linked to the appearance of intermediate density lipoprotein particles (ILDL). 
In uremia, protein synthesis may be impaired through a decreased amino-acid utilization 
and treatment with a low-protein diet could further accentuate the unfavourable influ­
ence on protein metabolism (cf. Introduction). 
However, the treatment with the amino-acid supplemented diet led to an improvement 
of not only the uremic symptoms but also of nitrogen balance with a reduced accumu­
lation of nitrogenous metabolites (paper II). The maintained low serum urea levels and 
the maintained body cell mass and serum proteins would furthermore indicate a lasting 
anabolic effect of the treatment (paper III). 
The reduced accumulation of metabolites during treatment would also contribute to the 
improvement of uremic toxicity. As shown in the present study, this could in tum imply 
a favourable effect on the intermediary metabolism, so that the large amounts of fat and 
sucrose in the diet could be assimilated without further negative influence on neither 
serum lipid nor carbohydrate metabolism (paper IV, V). From these results it may also 
be concluded that these last-mentioned derangements of metabolism in uremia would 
rather be related to loss of renal function per se than to malnutrition. 
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SUMMARY 
Treatment with an essential amino-acid supplemented low-protein diet is effective for re­
lief of uremic symptoms. Long-term dietary treatment is, however, associated with sev­
eral problems: 
— recognition of the functional limits for successful treatment 
— a risk of protein depletion and malnutrition 
— aggravation of the disturbances in lipid and carbohydrate metabolism 
— possibilities of dietary adherence 
The aim of this investigation was to study these problems in a clinically homogeneous 
series of patients who could be treated under strict surveillance by the same team for a 
longish period of time. 
From the results of the investigation, the following conclusions are drawn: 
1. Accurate measurement of the glomerular filtration rate (GFR) in advanced renal in­
sufficiency should be performed with an external marker (51Cr—EDTA or inulin) 
and with collection of urine in t he clearance determination. 
2. The lower limit of GFR for successful dietary treatment was about 4 ml/min. 
3. A 20 g protein diet should be supplemented with the essential amino-acids and histi-
dine (EAAH) to achieve nitrogen balance. In routine treatment supplementation with 
1.3 g N as EAAH, i.e. 9.6 g essential amino-acid mixture according to Rose and 0.8 g 
histidine, is sufficient for most patients. 
4. Measurements of body composition are convenient for long-term observation during 
treatment. In most patients with early uremic symptoms the relatively normal body 
composition was maintained during long-term treatment up to 12 months, unless 
complications of catabolic nature, e.g. intercurrent disease or nutritional difficulties, 
occurred. Repeated determination of body cell mass appears to be a sensitive method 
for early detection of malnutrition. 
5. Adherence to the diet used appeared to have been good in a routine outpatient popu­
lation, indicating that dietary counselling was adequate and that the diet was suffi­
ciently palatable and varied even during prolonged treatment. 
6. Lipid and carbohydrate metabolism was deranged in uremia. Impaired glucose toler­
ance, hypertriglyceridemia, a low elimination rate of exogenous fat and a low content 
of apolipoprotein and cholesterol in high-density lipoproteins (HDL) were the prin­
cipal findings. Reduced catabolism of triglyceride-rich lipoproteins appeared to be the 
dominating cause of hypertriglyceridemia in renal failure. The abnormalities may at 
least partly be linked to disturbances in the different effects of insulin. 
7. Dietary treatment with a high energy intake from fat and sucrose did not have an un­
favourable influence on the deranged lipid and carbohydrate metabolism. 
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